• Funding for sexual & reproductive health R&D has grown rapidly since we began tracking it in 2018, nearly doubling from $451m to $889m, though this is partly due to an increase in the conditions we include
• Increased funding has focused on STIs, while contraceptive R&D has tumbled, as shifting private sector priorities have left a big gap in contraceptive product development
• Overall growth in SRH R&D has been driven by funding for platform technologies, which will need to be adapted to specific pathogens before they can make an impact
• Female-only conditions remain the most significant area of neglect, receiving only a small share of SRH funding
• The high proportion of basic research funding and small shares for clinical development in women’s health show how far we have left to go to develop new products
• The US NIH, the Gates Foundation, and the pharmaceutical industry accounted for 82% of global SRH funding in 2023, and an even larger share of SRH-specific R&D
• The US government plays – or played – a critical role in funding SRH R&D: what happens next will have a big impact on the SRH R&D landscape going forward

Access the full report here: https://www.impactglobalhealth.org/insights/report-library/a-new-era-srh